Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN1673682 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Interleukin-1 Receptor-Associated Kinase 3 (IRAK3) (C-Term) antibody
- Antibody type
- Polyclonal
- Antigen
- A synthetic peptide corresponding to a sequence at the C-terminus of human IRAK3.Immunogen affinity purified.
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- C-Term
- Isotype
- IgG
- Vial size
- 100 μg
- Storage
- At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for a longer time.
- Handling
- Avoid repeated freezing and thawing.
Submitted references IRAK-M is involved in the pathogenesis of early-onset persistent asthma.
Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M.
IRAK-M is a negative regulator of Toll-like receptor signaling.
Balaci L, Spada MC, Olla N, Sole G, Loddo L, Anedda F, Naitza S, Zuncheddu MA, Maschio A, Altea D, Uda M, Pilia S, Sanna S, Masala M, Crisponi L, Fattori M, Devoto M, Doratiotto S, Rassu S, Mereu S, Giua E, Cadeddu NG, Atzeni R, Pelosi U, Corrias A, Perra R, Torrazza PL, Pirina P, Ginesu F, Marcias S, Schintu MG, Del Giacco GS, Manconi PE, Malerba G, Bisognin A, Trabetti E, Boner A, Pescollderungg L, Pignatti PF, Schlessinger D, Cao A, Pilia G
American journal of human genetics 2007 Jun;80(6):1103-14
American journal of human genetics 2007 Jun;80(6):1103-14
Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M.
Deng JC, Cheng G, Newstead MW, Zeng X, Kobayashi K, Flavell RA, Standiford TJ
The Journal of clinical investigation 2006 Sep;116(9):2532-42
The Journal of clinical investigation 2006 Sep;116(9):2532-42
IRAK-M is a negative regulator of Toll-like receptor signaling.
Kobayashi K, Hernandez LD, Galán JE, Janeway CA Jr, Medzhitov R, Flavell RA
Cell 2002 Jul 26;110(2):191-202
Cell 2002 Jul 26;110(2):191-202
No comments: Submit comment
No validations: Submit validation data